Anche per il 2025 il gruppo GIMEMA partecipa al congresso della Società americana di ematologia (ASH – American Society of Hematology) con una ricca serie di lavori sulle malattie onco-ematologica.

L’edizione numero 67 del congresso si terrà dal 6 al 9 dicembre, in Orlando, Florida. L’edizione del 2025 sarà sia in presenza sia in modalità online. Con centinaia di sessioni, migliaia di abstract e innumerevoli incontri tematici, il congresso annuale dell’ASH è l’evento ematologico più importante al mondo. L’evento ospiterà oltre 30.000 professionisti della salute, medici, ricercatori, educatori, più di 275 espositori e più di 8 mila abstract presentati.

Il programma è consultabile sul sito dell’ASH, oltre che attraverso l’applicazione mobile dell’ASH.

 

I ricercatori GIMEMA partecipano con abstract sulla leucemia mieloide acuta, sulla leucemia mieloide cronica, sulla qualità di vita e sulla leucemia linfoblastica acuta.

 

Di seguito la lista degli abstract GIMEMA che verranno presentati al congresso ASH2025:
 
 
 

Sabato, 6 dicembre

 

POSTER – ID 1676

10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group
Michael Lübbert, MD

POSTER – ID 1709

Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study group
Julia Stomper, et al.

POSTER – ID2685

Health-related quality of life and symptom burden of patients with vexas: Real-world data from a multicenter observational study
Fabio Efficace, et al.

 
 

Domenica, 7 dicembre

 

ORALE – ID 138

The prognostic value for survival of frailty and patient-reported outcomes in relapsed/refractory multiple myeloma: Results from a prospective multicenter observational study
Fabio Efficace, et al.

ORALE – ID 439

First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients
Sabina Chiaretti, et al.

POSTER – ID 3516

A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trial
Chiara Sartor, et al.

POSTER – ID 3751

Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine
Paola Guglielmelli, et al.

POSTER – ID 3755

Different kinetic behavior of molecular reduction by BCR::ABL1 transcript types in frontline treatment of chronic myeloid leukemia patients: A GIMEMA labnet CML network database survey.
Fabio Stagno, et al.

POSTER – ID 4408

Quality and timing of patient-reported outcome reports in randomized controlled trials (RCTs) of patients with lymphoid malignancies: Analysis of 83 RCTs published between 2015 and 2025
Fabio Efficace, et al.
 
 
 

Lunedì, 8 dicembre

 

ORALE – ID 905

International, prospective study comparing nilotinib versus imatinib with early switch to nilotinib to obtain sustained treatment-free remission (TFR) in patients with chronic myeloid leukemia: The tfr rate at the end of follow-up
Massimo Breccia, et al.   |   Speaker Fabrizio Pane

ORALE – ID 1025

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial
Alessandro Vannucchi, et al.

POSTER – ID 5102

First report of the GIMEMA INO-first multicenter observational study analyzing infective and non-infective complications in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin.
Anna Candoni, et al.  |   Speaker Livio Pagano

POSTER – ID 5243

Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance
Francesco Mannelli, et al.

POSTER – ID 6278

The prognostic value of patient-reported fatigue for survival in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy
Fabio Efficace, et al

POSTER – ID 6279

Health-related quality of life trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy: Results from a prospective observational study
Fabio Efficace, et al.

POSTER – ID 6389

Socioeconomic inequalities and health-related quality of life profile of patients with Myelodysplastic Syndromes (MDS): Analysis of 504 patients with higher-risk MDS
Francesco Sparano, et al.  |  Speaker Fabio Efficace